ArticleDiscover oncology2025
Gene expression profiling and pathway analysis in head and neck squamous cell carcinoma: focus on disulfidptosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Identification and validation of disulfidptosis-related gene signature revealed DKK1 as a therapeutic target in head and neck squamous cell carcinoma.Scientific reports · 2026Article
- Advancing the frontiers of ovarian cancer therapy: a comprehensive synthesis of emerging cell death paradigms.Oncology reviews · 2026Review
- An Update of AI and Radiomics in Precision Oncology: Insights from Liver Tumors as Case Models.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to characterize the prognostic and therapeutic implications of disulfidptosis-related genes (DRGs) in head and neck squamous cell carcinoma (HNSCC). Using multi-omics data from the Cancer Genome Atlas (TCGA) (n = 500) and Gene Expression Omnibus (GEO) cohorts (n = 270), we performed unsupervised consensus clustering, functional enrichment, immune deconvolution, and survival analyses to identify DRG-driven molecular subtypes. A disulfidptosis score (DRGscore) was developed via principal component analysis of prognosis-associated genes and validated across immunotherapy cohorts. Key results revealed eight DRGs with prognostic significance (P < 0.05), including RAC1 and SLC7A11, which form interaction networks linked to redox regulation and immune evasion. Four DRGclusters stratified patients into subgroups with distinct survival outcomes (P = 0.002), immune profiles, and pathway activities. DRGscore effectively predicted survival (P < 0.001), immunotherapy response (anti-PD1/PD-L1 cohorts: P = 0.0099-0.018), and drug sensitivity (A443654 IC50 = 0.12 μM vs. AICAR = 8.3 μM). Mutational profiling identified TP53 and MUC16 as high-risk biomarkers. These findings establish DRGscore as a robust prognostic tool integrating disulfidptosis biology and immune contexture, enabling risk-stratified therapeutic strategies for HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.